Berubicin

Phase 2Small molecule

CCNS Pharmaceuticals, Inc.

Berubicin is one of 56 small molecule programs targeting Glioblastoma Multiforme. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Glioblastoma MultiformeActive, not recruiting

Glioblastoma MultiformePhase 2

Active, not recruiting

Competition

Competitive Landscape

292 competitors in Glioblastoma Multiforme

#DrugCompanyPhaseTrials

Bicnu

MMelissa K Accordino

Phase 3

10 2

Arava

Sanofi

Phase 3

1 3

Aralen

Sanofi

Phase 3

1 4

Ceenu

AAzurity Pharmaceuticals

Phase 3

6 5

Yervoy

Opdivo

Veliparib

2 8

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Enzastaurin

1 10

Thalomid

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioblastoma Multiforme1 trial

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Active, not recruiting·CCNS Pharmaceuticals, Inc.·Phase 2·NCT04762069·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Berubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Berubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Berubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CNS Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCNS Pharmaceuticals, Inc.

Berubicin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioblastoma Multiforme1 trial

References

Drug Info

Quick Facts

Related News